Further Reading

Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting -  click here to view

Attainment of Glycemic Goals in Type 2 Diabetes with Once-, Twice-, or Three-times-daily Dosing with Biphasic Insulin Aspart 70/30 (The 1-2-3 Study) -  click here to view

Biphasic insulin aspart 30 + metformin vs once-daily insulin glargine + glimepiride: a study in people with type 2 diabetes - Click here to view (powerpoint presentation)

ACE/AACE Road Map for the Prevention and Treatment of Type 2 Diabetes - Click here to view